NasdaqGM:ZLABBiotechs
How Investors Are Reacting To Zai Lab (ZLAB) Phase 3 VYVGART Hytrulo Autoimmune Myositis Data
Zai Lab Limited and Argenx recently reported positive topline Phase 3 ALKIVIA results for VYVGART Hytrulo in adults with autoimmune myositis, showing statistically significant and clinically meaningful improvements in Total Improvement Score over placebo in the combined IMNM and DM population along with a safety profile consistent with prior studies.
The data highlight VYVGART Hytrulo’s potential to become a targeted option in a disease area currently managed mainly with corticosteroids and...